Innovent and SanegeneBio collaborate to develop siRNA drug for treatment of hypertension
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Innovent also obtains an exclusive option to license in the future development, manufacturing and commercialization rights of SGB-3908
Subscribe To Our Newsletter & Stay Updated